Young-onset hypertension increases the risk of cardiovascular and kidney outcomes compared with late-onset hypertension in type 2 diabetes.

COVID-19, RSV, and influenza immunizations show continued safety and substantial effectiveness against hospitalization across various populations.

The CDC's annual report on abortion trends has been delayed until the spring, but nongovernment groups produced similar research.

Disease disclosure helps mediate the effect of discrimination on internalized stigma among individuals with IBD.

Plecanatide significantly improves abdominal pain, bloating, and bowel movement frequency among young adults with IBS-C, supporting a novel trisymptom endpoint.

The new World Health Organization guideline supports using GLP-1 drugs for long-term obesity care, emphasizing lifestyle, behavioral therapy.

Tyruko (natalizumab-sztn), a biosimilar to Tysabri (natalizumab), has been made available by Sandoz, according to developer Polpharma Biologics.

Olezarsen receives FDA Breakthrough Therapy status for adults with severe hypertriglyceridemia following positive results from CORE and CORE2 trials.

A 4-week multimodal prehabilitation program before ESD improves postoperative functional recovery, muscle strength, and mental QOL.

The FDA has approved Linzess (linaclotide) for treatment of irritable bowel syndrome with constipation (IBS-C) in patients 7 years of age and older.

A manufacturing issue with Abbott FreeStyle Libre 3 sensors led to inaccurate readings, affecting about 3 million sensors worldwide.

The FDA approved perioperative durvalumab with FLOT chemotherapy for eligible patients with resectable Stage II-IVA gastric and GEJ cancers.